Watch Gert Ossenkoppele, Lars Bullinger and Thomas Shroeder present on what is the go-to strategy in high-risk AML in 2022 at the ESH 3rd How to Diagnose and Treat Acute Leukaemias Meeting
This Jazz Pharmaceuticals sponsored, promotional symposium is intended for healthcare professionals only
Prescribing information and adverse event reporting details are available in the video
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
INT-VYX-2200049
Date of Preparation: April 2022
